<DOC>
	<DOCNO>NCT00585208</DOCNO>
	<brief_summary>The purpose research study evaluate safety efficacy ramelteon ( Rozeremâ„¢ ) add-on treatment sleep problem patient bipolar disorder . This study determine whether addition ramelteon ongoing medication ( ) bipolar disorder useful improve sleep .</brief_summary>
	<brief_title>Add-On Ramelteon Bipolar I Disorder With Clinically Significant Sleep Disturbance</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel-group , single site , 8-week trial add-on ramelteon outpatient adult ( 18-65 year old , inclusive ) lifetime bipolar I disorder , mild moderate manic symptom , currently experience clinically significant sleep disturbance . Approximately 60 subject screen obtain 30 subject enroll 8-week trial . Subjects randomize ramelteon placebo double-blind manner add-on current treatment . Any psychotropic medication subject take initiation participation protocol continue unchanged throughout course study , except instance medication require dose reduction management side effect . Efficacy safety assessment perform weekly , presence treatment-emergent adverse event monitor record .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Dyssomnias</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>1 . Subjects must 18 65 year age , inclusive . 2 . Subjects must lifetime bipolar I disorder define DSMIVTR criterion . 3 . Subjects ' manic symptom must mild moderate severity , define YMRS score 10 25 . 4 . Subjects must currently experience clinically significant sleep disturbance , define PSQI total score &gt; 5 . 5 . Subjects must receive least 1 mood stabilize medication , may include atypical antipsychotic ( e.g. , aripiprazole , clozapine , olanzapine , quetiapine , risperidone , ziprasidone ) and/or mood stabilizer/anticonvulsant ( e.g , lithium , carbamazepine , valproate/divalproex , lamotrigine , oxcarbazepine ) medication &gt; 1 week prior baseline . Continued administration benzodiazepine sedativehypnotics allow subject receive medication &gt; 2 week prior baseline . 6 . Subjects legally authorize representative must sign Informed Consent Document nature trial fully explain . 7 . If female , subject must : postmenopausal , surgically incapable childbearing , practice medically acceptable effective method ( ) contraception ( e.g. , hormonal method , barrier method , intrauterine device ) least 1 month prior study entry throughout study . 1 . Subjects experience clinically significant suicidal homicidal ideation . 2 . Subjects currently experience psychotic symptom . 3 . Subjects current DSMIVTR Axis I diagnosis delirium , dementia , amnesia , cognitive disorder ; DSMIVTR diagnosis substance dependence disorder within past 6 month ; , lifetime DSMIVTR psychotic disorder ( e.g. , schizophrenia schizoaffective disorder ) . 4 . Subjects serious general medical illness include hepatic , renal , respiratory , cardiovascular , endocrine , neurologic , hematologic disease determine clinical judgment investigator . 5 . Subjects hypo hyperthyroidism unless stabilize thyroid replacement &gt; 3 month . 6 . Subjects clinically significant abnormality prestudy physical exam , vital sign , EKG , laboratory study . 7 . Subjects allergic demonstrate hypersensitivity ramelteon . 8 . Subjects take medication interact ramelteon ( e.g. , ketoconazole , fluconazole , fluvoxamine , rifampin ) . 9 . Females pregnant nursing . 10 . Subjects receive experimental drug use experimental device within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>insomnia</keyword>
	<keyword>sleep disturbance</keyword>
	<keyword>bipolar disorder</keyword>
</DOC>